Rifaximin
- Generic Name
- Rifaximin
- Brand Names
- Xifaxan, Zaxine
- Drug Type
- Small Molecule
- Chemical Formula
- C43H51N3O11
- CAS Number
- 80621-81-4
- Unique Ingredient Identifier
- L36O5T016N
- Background
Rifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic, meaning that the drug will not pass the gastrointestinal wall into the circulation as is common for other types of orally administered antibiotics. It has multiple indications and is used in treatment of traveller's diarrhea caused by E. coli; reduction in risk of overt hepatic encephalop...
- Indication
Rifaximin has multiple indications by the FDA: for the treatment of patients (≥12 years of age) with traveller's diarrhea caused by noninvasive strains of Escherichia coli; for the reduction of overt hepatic encephalopathy recurrence in patients ≥18 years of age; and in May 2015 it was approved for irritable bowel syndrome with diarrhea (IBS-D) treatment in ...
- Associated Conditions
- Bacterial Infections, Clostridium difficile infection recurrence, Hepatic Encephalopathy (HE), Irritable Bowel Syndrome (IBS), Traveler's Diarrhea
- Associated Therapies
- -
Rifaximin and Cardiac Function in Patients with Heart Failure with Preserved Ejection Fraction
- Conditions
- Interventions
- First Posted Date
- 2024-10-22
- Last Posted Date
- 2024-10-22
- Target Recruit Count
- 40
- Registration Number
- NCT06652087
- Locations
- 🇷🇺
Moscow, Moscow, Russian Federation
Rifaximin in Cirrhosis: Effects on Endotoxin and Haemostatic Indexes
- Conditions
- Interventions
- First Posted Date
- 2024-10-08
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- University of Roma La Sapienza
- Target Recruit Count
- 20
- Registration Number
- NCT06630572
- Locations
- 🇮🇹
Sapienza University of Rome - Policlinico Umberto I Roma, Rome, Italy
Study of Clinical Features and Efficacy of Small Intestinal Bacterial Overgrowth in Patients With Abdominal Distension
- First Posted Date
- 2024-07-24
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06518850
Human Albumin Infusion in Liver Cirrhosis and Overt Hepatic Encephalopathy (HACHE)
- Conditions
- Interventions
- First Posted Date
- 2024-07-03
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- General Hospital of Shenyang Military Region
- Target Recruit Count
- 174
- Registration Number
- NCT06483737
- Locations
- 🇨🇳
Department of Gastroenterology, General Hospital of Northern Theater Command (formerly called General Hospital of Shenyang Military Area), Shenyang, Liaoning, China
Efficacy of Rifaximin vs Norfloxacin for Secondary Prophylaxis of SBP (NORRIF Trial)
- Conditions
- Interventions
- First Posted Date
- 2024-01-10
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- Institute of Liver and Biliary Sciences, India
- Target Recruit Count
- 280
- Registration Number
- NCT06199843
- Locations
- 🇮🇳
Dr Jaya Benjamin, New Delhi, Delhi, India
Effects of Rifaximin on Gut Microbiota and Emotion
- Conditions
- Interventions
- First Posted Date
- 2022-10-19
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Universitaire Ziekenhuizen KU Leuven
- Target Recruit Count
- 60
- Registration Number
- NCT05587036
- Locations
- 🇧🇪
UZ/KU Leuven, Leuven, Belgium
Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea
- First Posted Date
- 2021-12-09
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Alfasigma S.p.A.
- Target Recruit Count
- 216
- Registration Number
- NCT05150587
- Locations
- 🇺🇸
Skin Care Research, Boca Raton, Florida, United States
🇺🇸Metropolis Dermatology, Los Angeles, California, United States
🇺🇸DelRicht Research, Tulsa, Oklahoma, United States
Feasibility of a New Diagnostic Device to Assess Small Intestinal Dysbiosis in Routine Clinical Setting.
- First Posted Date
- 2021-06-02
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- Atmo Biosciences Pty Ltd
- Target Recruit Count
- 150
- Registration Number
- NCT04910815
- Locations
- 🇮🇳
Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
🇦🇺Princess Alexandra Hospital, Woolloongabba, Queensland, Australia
Rifaximin Therapy vs Low FODMAP Diet In IBS
- Conditions
- Interventions
- First Posted Date
- 2021-04-12
- Last Posted Date
- 2023-05-16
- Lead Sponsor
- University of Malaya
- Target Recruit Count
- 100
- Registration Number
- NCT04841980
- Locations
- 🇲🇾
University Malaya Medical Centre, Kuala Lumpur, Malaysia
Efficacy and Safety of E.Coli Nissle 1917 in Patients With Mild (Stage 1-2) or Minimal Hepatic Encephalopathy
- Conditions
- Interventions
- First Posted Date
- 2021-03-08
- Last Posted Date
- 2021-03-08
- Lead Sponsor
- Bogomolets National Medical University
- Target Recruit Count
- 42
- Registration Number
- NCT04787276
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.